RemeGen Completes Patient Enrollment in Two Phase III Clinical Trials Using Telitacicept for Treatment of IgA Nephropathy and Primary Sjögren’s Syndrome

RemeGen Co. Ltd., a commercial-stage biotechnology company, recently announced significant progress of Telitacicept, that two Phase III clinical trials in China for the treatment of IgA nephropathy and primary Sjögren’s syndrome have completed patient enrollments.